Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2019 02:00 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period

- ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML- Positive interim Phase 2a data for ASLAN003 in AML was presented at the 2018 ASH Annual...
January 02, 2019 03:48 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule

SINGAPORE, Jan. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
December 02, 2018 12:00 ET | Source: ASLAN Pharmaceuticals Limited

New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia

SINGAPORE, Dec. 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
November 27, 2018 04:47 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium

SINGAPORE, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
November 20, 2018 05:00 ET | Source: ASLAN Pharmaceuticals Limited

Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference

SINGAPORE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
November 08, 2018 06:05 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

SINGAPORE, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
November 01, 2018 10:20 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting

SINGAPORE, Nov. 01, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
October 30, 2018 03:54 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director

SINGAPORE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
October 22, 2018 07:00 ET | Source: ASLAN Pharmaceuticals Limited

New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients

SINGAPORE, Oct. 22, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
October 17, 2018 12:31 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis

SINGAPORE, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...